Valneva

We are a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs.

[Valneva @valnevaSE]

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency.

https://t.co/m0PDeVbzap

[Valneva @valnevaSE]

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates.

https://t.co/54iuPozj0q

[Valneva @valnevaSE]

Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026

https://t.co/kliCltuu6z

[Valneva @valnevaSE]

Valneva Announces Successful Outcome of its Annual General Meeting

https://t.co/n2p40TWTKL

[Valneva @valnevaSE]

Valneva Announces Availability of Documentation for its Annual General Meeting.

https://t.co/0wXst9SU2v

[Valneva @valnevaSE]

Valneva to Participate at U.S. and European Investor Conferences in June.

https://t.co/XkyIJQ2OBD

[Valneva @valnevaSE]

Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates.

https://t.co/5eEDXvAAiK

[Valneva @valnevaSE]

Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026.

Link to press release: https://t.co/bRKJ8Sau57

Link to live webcast: https://t.co/xG7aTWPNWK

[Valneva @valnevaSE]

Valneva Announces the Successful Completion of an €84 million Reserved Offering

https://t.co/fOQ0wt1uxe

[Valneva @valnevaSE]

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC.

https://t.co/e9YLC0kFUn

[Valneva @valnevaSE]

Valneva Reports Full Year 2025 Audited Consolidated Financial Results.

https://t.co/UrmshtYbfJ

[Valneva @valnevaSE]

Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026.

https://t.co/zSK1gpDrFx

[Valneva @valnevaSE]

Valneva to Participate in Upcoming Investor Conferences.

https://t.co/JeSLaGG9Uv

[Valneva @valnevaSE]

Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook.

https://t.co/e1fXQL1QWJ

[Valneva @valnevaSE]

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ® .

https://t.co/x0GQnPkWyo

[Valneva @valnevaSE]

From all of us here at Valneva, wishing you a wonderful holiday season and a very happy 2026✨

[Valneva @valnevaSE]

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®.

https://t.co/E2F8yH1VTZ

[Valneva @valnevaSE]

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate.

https://t.co/NOvOl9JMtM

[Valneva @valnevaSE]

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates.

https://t.co/L3EQ0X8NpE

[Valneva @valnevaSE]

@ValnevaUSA had a great evening with @ScotGovLondon at our Transatlantic Innovation event! Thank you Mark Boyce and Natalie de Graaf for sharing your insights during the evening! We look forward to continued work with Scotland and other partners in the years to come! 🤝